Quarterly report [Sections 13 or 15(d)]

Note 15 - Net Loss Per Share

v3.26.1
Note 15 - Net Loss Per Share
3 Months Ended
Mar. 31, 2026
Notes to Financial Statements  
Earnings Per Share [Text Block]

15.         Net Loss Per Share

 

The following table sets forth the computation of basic and diluted net loss per common share:

 

   

Three Months Ended

 
   

March 31,

 
   

2026

   

2025

 

Numerator:

               

Net loss applicable to common stockholders

  $ (6,885 )   $ (2,891 )

Adjustment for deemed dividend in connection with equity financings (*, **)

    (376 )     (226 )

Adjusted net loss used for basic and diluted calculation

  $ (7,261 )   $ (3,117 )
                 

Denominator:

               

Weighted-average number of common shares, basic and diluted

    3,563       1,693  
                 

Net loss per common share:

               

Basic and diluted

  $ (2.04 )   $ (1.84 )

 

(*) For the three months ended March 31, 2026, the deemed dividend represents the periodic accretion of the redeemable Series B Preferred Stock's carrying amount to its full redemption value of $5,852, which increases loss available to common stockholders used for the basic and diluted net loss per common share calculation. Refer to Note 11. Capitalization and Equity Structure – Series B Convertible Preferred Shares and Warrants for additional information regarding the January 2026 Series B Preferred Stock.

(**) For the three months ended March 31, 2025, the deemed dividend represents the Company's incremental fair value of the March 2025 Inducement Warrant over the gross proceeds received, which increases loss available to common stockholders used for the basic and diluted net loss per common share calculation. Refer to Note 11. Capitalization and Equity Structure – Series B Convertible Preferred Shares and Warrants for additional information regarding the March 2025 Inducement Warrant.

 

The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive as of the end of each period presented:

 

   

Three Months Ended

 
   

March 31,

 
   

2026

   

2025

 

Options to purchase common stock

    10       12  

Restricted stock units

    82       56  

Convertible Series B Preferred Stock

    712        

B. Riley Promissory Note conversion option

    243        

Warrants for common stock

    1,158       913  

Shares held in abeyance

          466  

Total common stock equivalents

    2,205       1,447